Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CFTR Modulators in Brazil: Not for Everyone-A Comparison of Ineligibility Across Different Regions.

Pediatric pulmonology - 1 Mar 2026

Souza Edna Lúcia D', Bomfim Victor Hugo Valença, Monte Luciana de Freitas Velloso, Mota Laís Ribeiro, Nunes Gabriel Souza Medrado, Regina Terse-Ramos, Procianoy Elenara da Fonseca Andrade, Silva-Filho Luiz Vicente Ribeiro Ferreira da

Abstract excerpt

OBJECTIVES: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. METHODS: This cross-sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Patient Selection

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 41806325
DOI: 10.1002/ppul.71557

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CFTR Modulators in Brazil: Not for Everyone-A Comparison of Ineligibility Across Different Regions.PMID 41806325Read ↗

Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators.Semantic proximity Read ↗

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.Semantic proximity Read ↗

Efficacy of elexacaftor/tezacaftor/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic CFTR mutation: a retrospective cohort analysisSemantic proximity Read ↗

Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries.Semantic proximity Read ↗

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFB): a clinical study protocolSemantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.Semantic proximity Read ↗

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension StudySemantic proximity Read ↗

Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.Semantic proximity Read ↗

Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.Semantic proximity Read ↗

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.Semantic proximity Read ↗

Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.Semantic proximity Read ↗

Genotype-dependent biochemical response to elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: A 24-month real-world study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.